Assessing the effect of Efficacy of Habb-e-Asgandh in Diabetic Peripheral Neuropathy
- Conditions
- Health Condition 1: - Health Condition 2: E114- Type 2 diabetes mellitus with neurological complications
- Registration Number
- CTRI/2022/03/041293
- Lead Sponsor
- Central Council of Research in Unani Medicine New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Clinically diagnosed patients of Diabetic Peripheral Neuropathy with type 2 Diabetes mellitus, having fasting blood sugar (FBS) from 140mg/dl up to 200mg/dl and post prandial (PPS) level from 200mg/dl up to 300mg/dl.
-Patients between the ages of 30 to 60 years.
1. Patients irrespective of gender.
2. Patients having blood urea, serum creatinine, SGOT, SGPT within normal limit.
3. Patients willing to participate in the study and follow the instructions.
1. Pregnant and lactating mothers
2. Pathological status: cardiovascular disease, renal disease, hepatic disease.
3. Patients below 30 years and above 60 years of age.
ï??Complications of Diabetes other than Diabetic peripheral neuropathy.
4. Causes of Neuropathy other than Diabetes.
5. Patients who refuse to give the written consent for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diabetic Peripheral Neuropathy will be assessed by Toronto Clinical Neuropathy ScoreTimepoint: on 0 day, 15th day, 30th day and 45th day.
- Secondary Outcome Measures
Name Time Method Haematological tests include Hb%, TLC, DLC, ESR and Biochemical tests include Fasting blood sugar, Post prandial blood sugar, blood urea, serum creatinine, serum bilurubin, SGOT, SGPT, Total protein, Alkaline phosphataseTimepoint: before (0th day) and after intervention (45th day)